查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916896

人类肺模型市场：按模型类型、技术、应用和最终用户划分 - 全球预测（2026-2032 年）

Human Lung Models Market by Model Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人类肺模型市场价值将达到 3.3232 亿美元，到 2026 年将成长至 3.6141 亿美元，到 2032 年将达到 5.6443 亿美元，年复合成长率为 7.86%。

关键市场统计数据
基准年 2025 3.3232亿美元
预计年份：2026年 3.6141亿美元
预测年份 2032 5.6443亿美元
复合年增长率 (%) 7.86%

简洁地介绍人类肺模型领域的最新进展，将技术进步、转化研究重点和决策者的策略要务连结起来。

生物学、工程学和计算科学的融合催生了人类肺部模型，这些模型正在重塑呼吸系统疾病的研究方式、治疗方法的开发以及安全性的评估。组织工程、类器官培养、微流体和高解析度成像技术的进步，共同建构了能够以前所未有的精度重现肺部结构、力学和细胞复杂性的模型。同时，In Silico方法和整合计算框架透过将分子数据与组织层面的行为联繫起来，增强了预测能力并提高了转换应用价值。

技术变革、共同研究模式和检验重点的转变正在加速肺部系统的转化应用和产业化应用。

随着微工程、3D培养系统和计算模拟技术的突破，以及监管环境和商业性压力的不断变化，人类肺模型的模式正在迅速改变。技术的成熟使得长期培养稳定性得以实现，细胞类型复杂性得以提高，血管和免疫成分得以整合，从而更真实地再现疾病进程。同时，生物列印和先进的支架製造技术能够以更高的通量建构解剖学相关的模型，从而可以进行跨不同疾病和治疗方法的比较研究。

2025年关税主导的供应链变化如何重塑了肺部模型研究生态系统的筹资策略、供应商网路和营运韧性

贸易和关税政策的变化会对维持复杂肺部模型系统所必需的科学设备、专用耗材和试剂的供应链产生重大影响。增加实验室设备、聚合物支架、生物列印材料和试剂进口成本的关税会导致实验週期延长和单次实验成本上升，尤其对于资源密集的3D培养和类器官维护而言更是如此。采购延误和成本压力往往会对缺乏多元化供应商网路和充足库存的小规模学术实验室和新兴生物技术公司造成不成比例的影响。

将建模方法、底层技术、转换应用和最终用户优先顺序与策略决策流程连结起来的综合細項分析

理解模型细分的细微差别对于确定投资优先顺序和设计转换路径至关重要。在考虑模型类型时，必须认识到每种模型的作用：用于急性转化测试的离体模型、用于假设生成和参数探索的In Silico平台、用于机制研究和筛检活动的体外系统、用于捕捉整个生物体环境的体内模型，以及能够重现患者来源复杂性的类器官培养物。在体外方法中，二维细胞株仍适用于高通量检测，而三维培养物则能提供更接近组织生理的结构和细胞间相互作用。原代细胞培养物具有人类特异性生物学特性，但需要谨慎选择供体来源并品管。三维培养物本身也在不断发展，例如基于支架的结构（可提供可控的机械性能）和无支架聚集体（强调自组织和细胞行为）。

美洲、欧洲、中东和非洲以及亚太地区各区域策略的差异和互补优势将影响发展和商业化路径。

区域趋势正在影响人类肺模型技术的开发、检验和商业化方式。美洲地区聚集了大量的学术医疗中心、创业投资的生物技术公司和医疗器材製造商，这得益于强大的临床试验生态系统，该系统能够促进临床检验，从而加速从原型到商业化的转化。这种环境强调与国家监管机构的协调一致、扩充性，并鼓励转化研究实验室和商业团队之间的合作，以加速产品开发。

概述促进平台成熟度、检验和商业性扩充性的组织能力和协作角色，这些能力和角色将加速整个生态系统的发展。

关键企业和机构参与者正在推动平台创新，促进转化研究流程，并塑造人类肺部模型技术的商业化路径。设备製造商和专用耗材供应商在定义平台功能以及透过标准化试剂和检验的硬体来支援可重复性方面发挥关键作用。专注于类器官衍生和干细胞技术的生物技术公司正在扩展与疾病相关的患者来源模型的范围，而专注于生物列印硬体和微流体装置工程的供应商则致力于实现结构和动态的精确性。

领导者可以采取切实可行的营运和策略措施，以提高平台互通性、检验严谨性、供应链弹性和与转换研究的一致性。

希望利用人类肺模型最新进展的领导者应采取一系列切实可行的策略，以平衡科学可信度和商业性可行性。首先，应优先考虑平台模组化和互通性，从而保护前期前期投资，使新技术无需大规模检验即可整合。其次，应投资严格、标准化的检验通讯协定，强调生物学可重复性和实验室间可比性。此类通讯协定可降低监管谈判中的风险，并增强伙伴关係中的价值主张。此外，各组织也应实现供应商关係多元化，制定库存策略以降低供应链中断的风险，并考虑区域采购和生产，以减少关税波动和物流延迟的影响。

结合文献综述、专家访谈和生态系统分析的严谨的多源调查方法，能够得出可靠的研究结果并减少解释偏差。

本分析的调查方法整合了多方面的证据，旨在对人体肺模型提供平衡客观的观点。此方法首先对原始文献、技术白皮书、监管指导文件和同行评审的研究文章进行系统性回顾，并以实证研究结果佐证技术说明和检验实践。随后，研究人员与包括学术研究人员、转化科学家、设备工程师和商业领袖在内的相关领域专家进行了深入访谈和结构化讨论，以揭示实际挑战、应用驱动因素和新兴的伙伴关係模式。

最终成果是将技术进步、供应链经验教训和策略重点相结合，重点是检验、互通性和转换影响。

总而言之，人类肺模型正从专门的研究工具转变为转化医学流程中不可或缺的组成部分，为药物发现、精准医疗和安全性评估提供资讯。 3D培养、生物列印、微流体、成像和计算建模等领域的技术进步正在融合，从而提高模型的生理相关性和数据丰富度。 2025年关税导致的供应链中断凸显了在地采购、多元化供应商网路和业务永续营运的重要性，促使各组织重新思考其采购和伙伴关係策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依模型类型分類的人类肺模型市场

  • Ex Vivo
  • In Silico
  • 体外
    • 2D细胞株
    • 3D文化
      • 鹰架底座
      • 无支架
    • 原代细胞培养
  • In vivo
  • 类器官

9. 按技术分類的人类肺模型市场

  • 生物列印
  • 计算建模
  • 影像
    • 电脑断层扫描
    • 磁振造影
    • 显微镜
  • 微流体技术

第十章 按应用分類的人类肺模型市场

  • 疾病模型
    • 癌症
    • COPD
    • 纤维化
    • 呼吸道感染疾病
  • 药物发现
  • 精准医疗
  • 毒性测试

第十一章 以最终使用者分類的人类肺模型市场

  • 学术和研究机构
  • CRO（受託研究机构）
  • 医院和诊所
  • 製药和生物技术公司

第十二章 区域性人类肺部模型市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 人类肺模型市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国人肺模型市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国人类肺部模型市场

第十六章：中国人体肺模型市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AlveoliX Sarl
  • CN Bio Innovations Limited
  • Emulate, Inc.
  • Epithelix Sarl
  • Hurel Corporation
  • InSphero AG
  • MatTek Corporation
  • MIMETAS BV
  • Nortis, Inc.
  • TissUse GmbH
Product Code: MRR-AE420CB153DB

The Human Lung Models Market was valued at USD 332.32 million in 2025 and is projected to grow to USD 361.41 million in 2026, with a CAGR of 7.86%, reaching USD 564.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 332.32 million
Estimated Year [2026] USD 361.41 million
Forecast Year [2032] USD 564.43 million
CAGR (%) 7.86%

A concise orientation to the evolving field of human lung models that connects technological advances, translational priorities, and strategic imperatives for decision-makers

Human lung models represent a convergence of biology, engineering, and computational science that is reshaping how respiratory disease is studied, how therapeutics are developed, and how safety is assessed. Advances in tissue engineering, organoid culture, microfluidics, and high-resolution imaging have collectively enabled models that recapitulate structural, mechanical, and cellular complexity of the lung at unprecedented fidelity. In parallel, in silico approaches and integrated computational frameworks are enhancing predictive capability by connecting molecular data to tissue-level behavior, thereby improving translational relevance.

This summary synthesizes key developments across model modalities, technologies, applications, end users, and geographies to provide a concise, actionable perspective for senior decision-makers. It highlights the forces driving adoption, the technical and regulatory barriers that persist, and the strategic moves organizations are executing to capture translational value. By focusing on reproducibility, scalability, and clinical relevance, stakeholders can better align research investments with opportunities in drug discovery, precision medicine, and safety assessment. Moreover, the evolving interplay between experimental and computational models is creating hybrid workflows that accelerate hypothesis testing and reduce dependence on traditional animal models. Consequently, leaders in academia, industry, and healthcare are repositioning capabilities to harness these complementary strengths and to de-risk late-stage development.

Transformative shifts in technologies, collaborative models, and validation priorities that are fast-tracking translational relevance and industrial adoption of lung systems

The landscape for human lung models is shifting rapidly as breakthroughs in microengineering, three-dimensional culture systems, and computational simulation converge with changing regulatory expectations and commercial pressures. Technological maturation is enabling long-term culture stability, improved cell-type complexity, and the integration of vasculature and immune components, which in turn allow for more faithful recapitulation of disease processes. At the same time, bioprinting and advanced scaffold fabrication techniques are making it feasible to create anatomically relevant constructs at increasing throughput, enabling comparative studies across conditions and therapeutic modalities.

Concurrently, computational modeling and machine learning are enhancing interpretation of multimodal data, enabling more robust in silico-to-in vitro bridging studies. Imaging modalities have progressed to deliver dynamic, longitudinal readouts that reduce reliance on endpoint-only assays. These developments are prompting a shift from isolated proof-of-concept demonstrations toward standardized, modular platforms that prioritize compatibility with regulatory and industrial workflows. As a result, cross-sector collaborations between instrument providers, reagent manufacturers, contract research organizations, and clinical investigators are becoming the norm. This trend emphasizes platform interoperability, data standards, and validation frameworks that support evidence generation for both efficacy and safety, which ultimately accelerates translation from bench to bedside.

How tariff-driven supply chain shifts in 2025 reshaped procurement strategies, supplier networks, and operational resilience across lung model research ecosystems

Policy changes in trade and tariffs can materially affect supply chains for scientific instruments, specialized consumables, and the reagents essential to maintaining complex lung model systems. Tariffs that increase import costs on laboratory equipment, polymeric scaffolds, bioprinting materials, and reagents can extend procurement timelines and elevate per-experiment costs, particularly for resource-intensive 3D cultures and organoid maintenance. Procurement delays and cost pressures tend to disproportionately impact smaller academic labs and emerging biotechnology firms that lack diversified supplier networks or extensive inventories.

In the context of the United States tariffs enacted in 2025, organizations responded by reshaping sourcing strategies, rationalizing inventory holdings, and accelerating qualification of alternate suppliers. This pivot created immediate demand for domestic manufacturing partners and for regional distributors that could provide rapid fulfillment and technical support. As a result, some service providers and contract research organizations restructured operational footprints to reduce cross-border exposure, while instrument vendors increased localized service hubs. Over time, these adjustments altered procurement patterns, with larger institutions leveraging their purchasing power to negotiate bundled service agreements and smaller teams seeking collaborations that provide shared access to capital-intensive platforms. Importantly, the cumulative effect emphasized supply-chain resilience and prompted renewed attention to backward compatibility of consumables with legacy instruments to avoid disruptive requalification efforts.

Integrated segmentation insights that map model modalities, enabling technologies, translational applications, and end-user priorities to strategic decision pathways

A nuanced understanding of segmentation is essential to prioritize investments and design translational pathways. When examining model types, it is important to recognize the distinct roles of ex vivo preparations for acute translational testing, in silico platforms for hypothesis generation and parameter exploration, in vitro systems for mechanistic and screening activities, in vivo models for whole-organism context, and organoid cultures for patient-derived complexity. Within in vitro approaches, two-dimensional cell lines remain valuable for high-throughput assays, whereas three-dimensional cultures provide architecture and cell-cell interactions that better mimic tissue physiology; primary cell cultures offer human-specific biology but require careful donor sourcing and quality control. Three-dimensional cultures themselves split into scaffold-based constructs that afford controlled mechanical properties and scaffold-free assemblies that emphasize self-organization and cellular behavior.

From a technology standpoint, bioprinting enables spatial patterning and scale, computational modeling offers predictive scaling and virtual experimentation, imaging provides structural and functional readouts, and microfluidics recreates flow and mechanical cues. Imaging modalities are not interchangeable; computed tomography offers macroscopic structural resolution in ex vivo contexts, magnetic resonance imaging supplies soft-tissue contrasts and functional mapping, and microscopy delivers cellular and subcellular insights. Application-driven segmentation clarifies pathway choices: disease modeling spans cancer, chronic obstructive pulmonary disease, fibrotic processes, and respiratory infections, each demanding different cell compositions and readouts. Drug discovery workflows prioritize throughput and assay robustness, precision medicine emphasizes patient-specific models and biomarker linkage, and toxicity testing requires standardized endpoints and regulatory alignment. Finally, the end-user landscape ranges from academic and research institutes focused on mechanism and methodology development, through contract research organizations that translate platforms into service offerings, to hospitals and clinics seeking clinically relevant diagnostics and therapeutic validation, and pharmaceutical and biotechnology companies that integrate models into preclinical decision making. Understanding how these segments intersect guides decisions on platform design, validation pathways, and partnership models.

Regional strategic contrasts and complementary strengths across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence development and commercialization pathways

Regional dynamics are shaping how human lung model innovations are developed, validated, and commercialized. In the Americas, a dense concentration of academic medical centers, venture-backed biotechnology firms, and instrument manufacturers fosters rapid prototype-to-commercial transitions, supported by robust clinical trial ecosystems that facilitate clinical validation. This environment prioritizes scalability and regulatory alignment with domestic authorities and incentivizes partnerships between translational research labs and commercial teams to accelerate productization.

In Europe, Middle East & Africa, the landscape is characterized by strong public research funding, collaborative consortia, and a cautious regulatory framework that emphasizes human-relevant models and reduction of animal testing. Cross-border initiatives and harmonized standards are driving adoption of interoperable platforms and shared validation studies, while regional manufacturing hubs are emerging to support localized supply chains. In Asia-Pacific, large-scale investments in biotech manufacturing capacity, rapid clinical development timelines, and an expanding base of CROs have created an environment that emphasizes cost-effectiveness and rapid iteration. Many organizations in the region are investing heavily in automation and high-throughput platforms to support large-scale screening and regional clinical partnerships. Collectively, these regional contrasts create complementary strengths and underscore the importance of geographically informed commercialization and partnership strategies that account for regulatory nuance, supply-chain realities, and local clinical priorities.

Profiles of the organizational capabilities and collaborative roles that are accelerating platform maturity, validation, and commercial scalability across the ecosystem

Key corporate and institutional actors are driving platform innovation, enabling translational pipelines, and shaping commercial pathways for human lung model technologies. Instrument manufacturers and specialty consumable suppliers are crucial in defining platform capabilities and supporting reproducibility through standardized reagents and validated hardware. Biotechnology companies focused on organoid derivation and stem cell technologies are expanding the range of disease-relevant, patient-derived models, while engineering-focused vendors of bioprinting hardware and microfluidic devices are enabling architectural and biomechanical fidelity.

Service providers and contract research organizations are evolving from simple assay vendors into strategic partners that offer integrated workflows spanning model development, assay validation, and regulatory documentation. Imaging and analytics firms are enhancing the ability to extract actionable readouts from complex, multimodal data, creating value through software platforms and analytical pipelines. Academic centers and translational research institutes continue to contribute foundational methods and early validation studies, often in collaboration with industry partners to accelerate commercial deployment. Collectively, these players are coalescing around validation frameworks, data standards, and interoperability practices that reduce friction for adoption and support broader reproducibility across labs and organizations.

Actionable operational and strategic moves that leaders can deploy to improve platform interoperability, validation rigor, supply resilience, and translational alignment

Leaders seeking to capitalize on advances in human lung models should adopt a set of pragmatic, tactical actions to align scientific credibility with commercial viability. First, prioritize platform modularity and interoperability so that new technologies can be integrated without extensive requalification, thereby protecting earlier investments. Next, invest in rigorous, standardized validation protocols that emphasize biological reproducibility and cross-laboratory comparability; such protocols de-risk regulatory conversations and strengthen value claims in partnerships. Organizations should also diversify supplier relationships and build inventory strategies to mitigate supply-chain shocks, while exploring regional sourcing and manufacturing to reduce exposure to tariff volatility and logistics delays.

Furthermore, foster translational collaborations that pair technical developers with clinical and regulatory experts early in the product lifecycle, enabling endpoint alignment and smoother pathways to clinical relevance. Embrace hybrid workflows that combine in vitro, organoid, in silico, and imaging modalities to generate richer evidence packages that support both efficacy and safety assessments. Lastly, develop clear commercialization strategies that delineate productized platforms, service offerings, and data licensing models, and ensure these strategies are informed by regional regulatory nuance and end-user procurement practices. By executing these actions, organizations can accelerate adoption, reduce technical risk, and capture greater translational value from their investments.

A rigorous, multi-source research methodology combining literature synthesis, expert interviews, and ecosystem analysis to derive robust insights and reduce interpretive bias

The research methodology underpinning this analysis integrates multiple evidence streams to provide a balanced and objective perspective on human lung models. The approach began with a systematic review of primary literature, technical white papers, regulatory guidance documents, and peer-reviewed studies to ground technological descriptions and validation practices in empirical findings. Next, in-depth interviews and structured discussions with domain experts-spanning academic investigators, translational scientists, instrument engineers, and commercial leaders-were conducted to surface practical challenges, adoption drivers, and emergent partnership models.

Complementing qualitative inputs, technology and workflow analyses were performed to map capability overlaps, identify integration points across modalities, and assess operational dependencies such as consumable lifecycles and maintenance requirements. Regional ecosystem assessments were informed by public funding announcements, patent activity, and observed shifts in corporate strategy to characterize geographic strengths and supply-chain considerations. Throughout, triangulation across data sources was used to corroborate insights and to mitigate bias. Where appropriate, sensitivity checks and validation interviews were employed to refine interpretations and ensure the conclusions reflect consensus perspectives from multiple stakeholder groups.

A distilled synthesis of technological progress, supply-chain lessons, and strategic priorities that emphasizes validation, interoperability, and translational impact

In summary, human lung models are transitioning from specialized research tools to integral components of translational pipelines that inform drug discovery, precision medicine, and safety assessment. Technological advances in three-dimensional culture, bioprinting, microfluidics, imaging, and computational modeling are collectively enhancing physiological relevance and data richness. Tariff-induced supply-chain disruptions in 2025 emphasized the need for localized sourcing, diversified supplier networks, and operational resilience, prompting organizations to rethink procurement and partnership strategies.

Strategic segmentation across model type, technology, application, and end user reveals distinct priorities and interoperability requirements that should guide investment and collaboration decisions. Region-specific strengths create opportunities for complementary partnerships that bridge prototype development with scale-up and clinical validation. Ultimately, organizations that prioritize standardized validation, cross-platform interoperability, and early clinical alignment will be best positioned to translate technical advances into sustainable clinical and commercial outcomes. This synthesis is intended to support executive decision-making and to catalyze targeted actions that accelerate the real-world impact of human lung model innovations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Lung Models Market, by Model Type

  • 8.1. Ex Vivo
  • 8.2. In Silico
  • 8.3. In Vitro
    • 8.3.1. 2D Cell Lines
    • 8.3.2. 3D Cultures
      • 8.3.2.1. Scaffold-Based
      • 8.3.2.2. Scaffold-Free
    • 8.3.3. Primary Cell Cultures
  • 8.4. In Vivo
  • 8.5. Organoid

9. Human Lung Models Market, by Technology

  • 9.1. Bioprinting
  • 9.2. Computational Modeling
  • 9.3. Imaging
    • 9.3.1. Computed Tomography
    • 9.3.2. Magnetic Resonance Imaging
    • 9.3.3. Microscopy
  • 9.4. Microfluidics

10. Human Lung Models Market, by Application

  • 10.1. Disease Modeling
    • 10.1.1. Cancer
    • 10.1.2. COPD
    • 10.1.3. Fibrosis
    • 10.1.4. Respiratory Infections
  • 10.2. Drug Discovery
  • 10.3. Precision Medicine
  • 10.4. Toxicity Testing

11. Human Lung Models Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Human Lung Models Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Lung Models Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Lung Models Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Lung Models Market

16. China Human Lung Models Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AlveoliX Sarl
  • 17.6. CN Bio Innovations Limited
  • 17.7. Emulate, Inc.
  • 17.8. Epithelix Sarl
  • 17.9. Hurel Corporation
  • 17.10. InSphero AG
  • 17.11. MatTek Corporation
  • 17.12. MIMETAS B.V.
  • 17.13. Nortis, Inc.
  • 17.14. TissUse GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN LUNG MODELS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN LUNG MODELS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN SILICO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN SILICO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN SILICO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 2D CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 2D CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 2D CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ORGANOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ORGANOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ORGANOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY BIOPRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY BIOPRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY BIOPRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTATIONAL MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTATIONAL MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTATIONAL MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRECISION MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PRECISION MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 210. G7 HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 213. G7 HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 215. G7 HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 219. NATO HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN LUNG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA HUMAN LUNG MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HUMAN LUNG MODELS MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HUMAN LUNG MODELS MARKET SIZE, BY IN VITRO, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA HUMAN LUNG MODELS MARKET SIZE, BY 3D CULTURES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA HUMAN LUNG MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA HUMAN LUNG MODELS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA HUMAN LUNG MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA HUMAN LUNG MODELS MARKET SIZE, BY DISEASE MODELING, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA HUMAN LUNG MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)